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Abstract 
Objective: This systematic review and meta-analysis seeks to determine the validity of the anion gap to screen for 
hyperlactatemia in critically ill patients. We have previously shown that the anion gap does not predict 31-day and 
in-hospital mortality in critically ill patients. The present review aims to add confirmatory evidence to identify whether 
the anion gap is a suitable tool for risk stratification in low-resource countries.
Results: Nine studies reporting on 4504 samples from 2111 patients were included. The anion gap failed to detect 
hyperlactatemia defined as lactate above 2.5 mmol/l but showed good discriminatory ability for the detection of 
severe hyperlactatemia defined as lactate over 4 mmol/l. At the 2.5 mmol/l threshold, the anion gap had high speci-
ficity but low sensitivity for the detection of hyperlactatemia. A meta-analysis of correlation coefficients yielded high 
statistical heterogeneity. Therefore, in keeping with our previous findings, the use of the anion gap for risk stratifica-
tion as an alternative to lactate cannot be recommended. However, the strength of the evidence we have synthe-
sised is adversely affected by the small number of studies included, inconsistency of effect measures and positivity 
thresholds reported, and selection bias within individual studies. PROSPERO Registration Number: CRD42015016470 
(registered on the 4th February 2015).
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Introduction
The anion gap (AG) reflects the concentration of unmeas-
ured anions and is easily calculated from routine clinical 
chemistry analytes. Traditionally, the AG has been used 
as an alternative to lactate analysis; however, with the 
widespread availability of facilities for lactate analysis, the 
AG is now rarely used for this purpose in high-income 
countries. Nonetheless, in low-resource settings, where 
facilities for lactate analysis are frequently not avail-
able, the AG may have potential as a screening tool for 
hyperlactatemia in critically ill patients. Previous studies 
regarding the validity of AG as a screening tool for hyper-
lactatemia have yielded equivocal results [1, 2].
Our present review was intended to add confirmatory 
evidence to determine whether, in low-resource set-
tings, efforts should be focused on making the best use 
of available resources to measure AG, or to widen access 
to lactate analysis. In a previous systematic review and 
meta-analysis, [3] we determined that the AG does not 
predict 31-day mortality, in-hospital mortality and com-
parable outcome measures. However, the findings of the 
previous review were limited by the poor methodologi-
cal quality of included studies and significant statistical 
heterogeneity in meta-analysis. In the present review, we 
aimed to determine the validity of the observed and albu-
min-corrected AG to screen for hyperlactatemia in criti-
cally ill patients in a systematic review and meta-analysis.
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Methods
This systematic review and meta-analysis adheres to 
the Preferred Reporting Items for Systematic reviews 
and Meta-analyses (PRISMA) standards [4]. A protocol 
was registered with PROSPERO, Registration Number 
CRD42015016470. Studies were eligible if the observed 
and/or albumin-corrected AG level was compared to 
arterial, venous or capillary lactate concentration in criti-
cally ill patients. Studies were excluded if the blood sam-
ples for AG and lactate were drawn more than 2 h apart. 
The search strategy, study selection and data extrac-
tion processes are described in our previous review [3] 
although in the current review no restriction on publica-
tion date was applied. Methodological quality was rated 
independently by two reviewers using a modified version 
of the Quality Assessment of Diagnostic Accuracy Stud-
ies (QUADAS-2) tool [5]. Agreement between reviewers 
was quantified using Cohen’s kappa and discrepancies 
were resolved by discussion.
Due to the inconsistency of effect measures and posi-
tivity thresholds reported by individual studies we have 
used a variety of statistical measures to summarise and 
synthesise the findings of included studies. Where a 
statistical synthesis would have been associated with 
substantial limitations we have opted for a narrative or 
graphical synthesis instead. Where statistical synthesis 
was possible, we used a random effects model where het-
erogeneity was high or moderate and a fixed and random 
effects model where heterogeneity was low. Heterogene-
ity was quantified using the  I2 test. Forest plots display-
ing sensitivity and specificity were generated for studies 
reporting a common positivity threshold for both the 
AG and hyperlactatemia; a summary effect measure was 
not calculated. Likelihood ratios were calculated for each 
study. A Moses Littenberg summary ROC curve was gen-
erated for studies reporting a hyperlactatemia positivity 
threshold of 2.5 mmol/l [6]. Studies reporting sensitivity 
and specificity at a broad range of AG positivity thresh-
old were selected so as to depict graphically the trade-off 
between sensitivity and specificity over a wide range of 
clinically relevant thresholds. A summary AUC value was 
not calculated. Studies reporting area under the ROC 
curve (AUC) for similar lactate thresholds were pooled in 
a generic inverse variance meta-analysis. Fisher’s Z-trans-
formed Pearson product-moment correlation coefficients 
were also pooled in a generic inverse variance meta-anal-
ysis. Subgroup analysis was undertaken to assess whether 
heterogeneity in the meta-analysis of correlation coeffi-
cients could be explained by study setting or patient age. 
The summary ROC curve and the forest plots for sensi-
tivity and specificity were generated in Review Manager 
5.3 and correlation coefficients and AUCs were pooled 
in MedCalc version 15.4. All data are presented as effect 
estimates with 95% confidence intervals.
Results
The results of the initial database search up to the com-
mencement of full-text screening are described in our 
previous study [4] and in Additional file  1: Fig. S1. Six-
teen articles were retrieved in full-text, of which two 
were excluded because the time between drawing sam-
ples for AG and lactate was not specified. A further five 
studies were excluded during data extraction: three stud-
ies were excluded because no relevant effect measure 
could be extracted, one study was excluded because only 
patients with metabolic acidosis were included and one 
study was excluded because only patients with lactate 
above 2.5  mmol/l were included. Therefore, nine stud-
ies were included in the systematic review (Additional 
file  2: Fig. S2). The characteristics of included studies 
are described in Additional file  3: Table S1. Five stud-
ies (56%) reported arterial lactate levels, one reported 
venous lactate levels, one reported both venous and arte-
rial lactate levels and one did not specify the source. In 
all but two studies the samples for AG and lactate were 
drawn concomitantly or consecutively. In two studies a 
maximum time-frame of 30 min and 60 min respectively 
was given. Hyperlactatemia was defined as lactate above 
2.5 mmol/l by six (67%) studies, as lactate above 4 mmol/l 
by one study (11%) and above 5  mmol/l by two studies 
(22%); the latter two thresholds will be referred to as 
severe hyperlactatemia here. The methodological quality 
of included studies is illustrated in Additional file 4: Fig. 
S3. Inter-rater agreement between reviewers was mod-
erate (κ  =  0.49), with differences in judgement mainly 
concerning the flow and timing domain. The patient 
selection and flow and timing domains were most fre-
quently rated at risk of high or unclear bias.
Six studies reported sensitivity and specificity for a 
2.5  mmol/L hyperlactatemia threshold, of which three 
studies reported an AG positivity threshold of 12 mEq/L 
and three studies reported an AG positivity threshold of 
16 mEq/L (Fig. 1). For the former three studies, specific-
ity was higher than 0.8 in all three studies but sensitiv-
ity was low with values ranging from 0.39 to 0.57. Results 
of the latter group appear heterogeneous with sensitivity 
values ranging from 0.27 to 0.85 and specificity rang-
ing from 0.5 to 0.91. The positive likelihood ratios cal-
culated for the above studies were all smaller than 10 
and the negative likelihood ratios were larger than 0.1 
and thus below the threshold recommended for clinical 
use. A Moses Littenberg summary ROC curve, includ-
ing studies reporting AG positivity thresholds between 6 
and 20 mEq/L, is shown in Additional file 5: Fig. S4. The 
trade-off between sensitivity and specificity appears to 
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be poor. Judging from the magnitude of scatter of points 
among the predicted curve, there appears to be low to 
moderate heterogeneity.
All three studies reporting AG in relation to severe 
hyperlactatemia reported AUCs, which were pooled in 
meta-analysis (Fig.  2); the summary AUC is 0.87 (0.82, 
0.91) and no heterogeneity was observed  (I2 = 0%).
Seven studies reported correlation coefficients; these 
were combined in meta-analysis (Fig.  3). In view of the 
high heterogeneity  (I2 = 97.8%) the pooled effect estimate 
should not be interpreted. Most heterogeneity was due to 
the study by Martin 2005 [7]. Subgroup analysis on this 
meta-analysis demonstrated that neither study setting 
nor patient age influenced the summary correlation coef-
ficient (p = 0.47 and 0.56 respectively), and heterogeneity 
remained high in all subgroups (data not shown).
Insufficient data were available for analysis of the valid-
ity of albumin-corrected AG.
Discussion
The AG failed to detect hyperlactatemia defined as lac-
tate above 2.5  mmol/l but showed good discriminatory 
ability for the detection of severe hyperlactatemia defined 
as lactate over 4 mmol/l. At the 2.5 mmol/l lactate thresh-
old, the trade-off between sensitivity and specificity was 
poor and when sensitivity and specificity were analysed 
individually, the AG had high specificity but low sensitiv-
ity for the detection of hyperlactatemia. Importantly, a 
high hyperlactatemia threshold such as 4 mmol/l would 
miss patients at risk of adverse outcomes. Nichol and col-
leagues found that even patients with elevated lactate lev-
els within the normal reference range are at higher risk of 
mortality compared to those with low lactate levels [8].
The poor screening power of the AG may be due to the 
variability in baseline AG levels between normal individ-
uals. Where a patient’s baseline AG is low, an increment 
Fig. 1 Forest plot of sensitivity and specificity of the observed AG at thresholds of 12 and 16 mEq/l to detect hyperlactataemia defined as lac-
tate > 2.5 mmol/l (TP true positive, FP false positive, FN false negative, TN true negative, CI confidence interval)
Fig. 2 Forest plot showing random and fixed effects generic inverse 
variance meta-analyses for AUCs of the observed AG detecting severe 
hyperlactataemia defined as lactate > 4 mmol/l or 5 mmol/l,  I2 = 0%
Fig. 3 Forest plot for random effects generic inverse variance meta-
analysis of correlation coefficients assessing the association between 
AG and lactate levels,  I2 = 98%
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of up to 8 mEq/l may be necessary for the AG to fall out-
side the normal range [9]. Thus, a patient may become 
considerably hyperlactatemic before the AG positiv-
ity threshold is reached. Conversely, in patients with a 
high baseline AG, a small increase in lactate is sufficient 
to raise the AG above its positivity threshold. The ∆AG 
may be preferable but it was shown that in some patients, 
hyperlactatemia was not accompanied by a change in 
∆AG [10].
Furthermore, the finding by Maciel and Park that lac-
tate is only responsible for a minor percentage of meta-
bolic acidosis may explain the poor screening power 
of the AG. In fact, unmeasured anions account for the 
majority of metabolic acidosis in critically ill intensive 
care unit patients [11]. Similarly, changes in albumin con-
centration are likely to be implicated in the poor screen-
ing power of the AG. The largest study included in this 
review [7] reported a larger correlation between albu-
min-corrected AG and lactate compared to the uncor-
rected AG. However, other studies found that correcting 
the AG for albumin did not improve the detection of 
hyperlactatemia [12].
The high heterogeneity in the meta-analysis of correla-
tion coefficients remains largely unexplained. Subgroup 
analysis was undertaken to determine whether patient 
age or clinical setting influence the pooled effect estimate 
but too few studies were available to conduct subgroup 
analysis on further factors. Other factors, which may 
explain heterogeneity include the type of clinical chemis-
try analysis, differences between arterial, venous and cap-
illary lactate and baseline albumin level.
Overall, the studies included in the present review are 
of higher quality than those included in our previous 
review, in which we investigated the ability of the AG 
to predict 31-day or in-hospital mortality [3]. The main 
reason may be that fewer variables need to be accounted 
for to establish the relationship between AG and lactate 
whereas mortality is affected by multiple factors, which 
can be difficult to control for.
Taken together, the results of the present and previ-
ous reviews suggest that the AG should not be recom-
mended for risk stratification. Instead, we believe that 
future research should focus on widening access to lac-
tate analysis, for example in the form of hand-held point-
of-care devices. A study of septic patients admitted to the 
emergency department found that point-of-care lactate 
devices reduced the time to administration of intrave-
nous fluids, intensive care unit admission and mortality 
[13]. Point-of-care testing was found to improve health 
outcomes in low-income countries [14] and the authors 
felt that introducing point-of-care testing for lactate in 
a tertiary obstetric unit in Malawi was feasible and well 
received by staff [15].
Conclusion
The AG has low sensitivity to detect hyperlactatemia at 
a clinically relevant positivity threshold of 2.5  mmol/l 
but has good discriminatory ability for the detection of 
severe hyperlactatemia defined as lactate over 4 mmol/l. 
In keeping with the findings of our previous study on 
the validity of the AG to predict mortality in critically 
ill patients, the use of the AG as an alternative to lactate 
measurement cannot be recommended.
Limitations
The main limitation of this review is the small number 
of studies included and inconsistency of effect meas-
ures and AG positivity thresholds reported by individual 
studies. Several studies failed to report sensitivity and 
specificity or failed to report the prevalence of hyperlac-
tatemia in the study population for all lactate positivity 
thresholds examined. Furthermore, some studies did not 
enrol a consecutive or random sample of patients and 
failed to specify whether data for all patients was avail-
able for analysis, which may have led to sampling bias. 
Whilst in most studies the samples for AG and lactate 
were drawn concomitantly, in two studies a maximum 
time-frame of 30 and 60 min was given respectively. One 
study [16] reported that whilst it was standard practice 
to draw the samples simultaneously, there may have been 
exceptions. Interventions and treatment during resusci-
tations in critically ill patients may result in changes to 
the physiology that make such results unreliable. Lastly, 
two studies had to be excluded because the time between 
the measurement of AG and lactate was not specified.
The review methodology was limited by its language 
restriction to articles published in English, German or 
French, which may have introduced publication bias. 
Furthermore, the study selection process was undertaken 
by a single reviewer, which may have increased the risk of 
missing relevant studies.
Additional files
Additional file 1: Fig. S1. Flow chart of search and selection process of 
our previous study on the ability of the anion gap to predict 31-day and 
in-hospital mortality.
Additional file 2: Fig. S2. Flow chart of the search and selection process 
of the present study.
Additional file 3: Table S1. Characteristics of included studies. HL 
(hyperlactatemia), ICU (intensive care unit), NA (data not available).
Additional file 4: Fig. S3. Risk of bias and applicability concerns graph: 
reviewers’ judgements on quality domains relevant to diagnostic accuracy 
studies for each included study.
Additional file 5: Fig. S4. Moses Littenberg-based summary ROC curve 
for the ability of observed AG to detect hyperlactataemia defined as 
lactate > 2.5 mmol/l.
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